Video_2_GSK3β Interacts With CRMP2 and Notch1 and Controls T-Cell Motility.mp4
The trafficking of T-cells through peripheral tissues and into afferent lymphatic vessels is essential for immune surveillance and an adaptive immune response. Glycogen synthase kinase 3β (GSK3β) is a serine/threonine kinase and regulates numerous cell/tissue-specific functions, including cell survival, metabolism, and differentiation. Here, we report a crucial involvement of GSK3β in T-cell motility. Inhibition of GSK3β by CHIR-99021 or siRNA-mediated knockdown augmented the migratory behavior of human T-lymphocytes stimulated via an engagement of the T-cell integrin LFA-1 with its ligand ICAM-1. Proteomics and protein network analysis revealed ongoing interactions among GSK3β, the surface receptor Notch1 and the cytoskeletal regulator CRMP2. LFA-1 stimulation in T-cells reduced Notch1-dependent GSK3β activity by inducing phosphorylation at Ser9 and its nuclear translocation accompanied by the cleaved Notch1 intracellular domain and decreased GSK3β-CRMP2 association. LFA-1-induced or pharmacologic inhibition of GSK3β in T-cells diminished CRMP2 phosphorylation at Thr514. Although substantial amounts of CRMP2 were localized to the microtubule-organizing center in resting T-cells, this colocalization of CRMP2 was lost following LFA-1 stimulation. Moreover, the migratory advantage conferred by GSK3β inhibition in T-cells by CHIR-99021 was lost when CRMP2 expression was knocked-down by siRNA-induced gene silencing. We therefore conclude that GSK3β controls T-cell motility through interactions with CRMP2 and Notch1, which has important implications in adaptive immunity, T-cell mediated diseases and LFA-1-targeted therapies.
History
References
- https://doi.org//10.1056/NEJM200010053431407
- https://doi.org//10.1038/nri.2015.16
- https://doi.org//10.4049/jimmunol.1700495
- https://doi.org//10.1038/35096075
- https://doi.org//10.1038/nrn2870
- https://doi.org//10.1242/jcs.138057
- https://doi.org//10.12688/f1000research.10557.1
- https://doi.org//10.1159/000356550
- https://doi.org//10.4049/jimmunol.1501264
- https://doi.org//10.1007/978-1-4939-9036-8_2
- https://doi.org//10.3389/fimmu.2018.00397
- https://doi.org//10.1007/978-1-4939-9036-8_3
- https://doi.org//10.1007/978-1-4939-9036-8_5
- https://doi.org//10.1007/978-1-4939-9036-8_7
- https://doi.org//10.1002/jcp.22478
- https://doi.org//10.1042/bj3510095
- https://doi.org//10.1042/BJ20070797
- https://doi.org//10.1371/journal.pone.0058501
- https://doi.org//10.1172/jci.insight.132796
- https://doi.org//10.1042/BC20100016
- https://doi.org//10.1038/srep08666
- https://doi.org//10.1242/jcs.229948
- https://doi.org//10.1038/srep40716
- https://doi.org//10.1038/ncb3149
- https://doi.org//10.1097/FJC.0000000000000429
- https://doi.org//10.1016/j.jcyt.2019.12.007
- https://doi.org//10.1016/j.yjmcc.2020.03.003
- https://doi.org//10.18632/oncotarget.13958
- https://doi.org//10.1016/j.bbrc.2019.06.038
- https://doi.org//10.1371/journal.pone.0084659
- https://doi.org//10.1371/journal.pone.0162508
- https://doi.org//10.1074/mcp.M500061-MCP200
- https://doi.org//10.1016/j.immuni.2016.01.018
- https://doi.org//10.1186/s13104-020-04971-0
- https://doi.org//10.1074/jbc.M112.348946
- https://doi.org//10.1096/fj.201701078R
- https://doi.org//10.1016/j.cellsig.2018.01.012
- https://doi.org//10.1371/journal.pone.0080500
- https://doi.org//10.1016/j.bbrc.2020.07.142
- https://doi.org//10.1038/s41467-018-03512-5
- https://doi.org//10.1074/jbc.M304001200
- https://doi.org//10.1098/rsob.190187
- https://doi.org//10.1016/s1074-7613%2804%2900081-0
- https://doi.org//10.1016/S0960-9822%2802%2900888-6
- https://doi.org//10.1038/89624
- https://doi.org//10.1016/j.molcel.2004.10.014
- https://doi.org//10.1002/cam4.3916
- https://doi.org//10.1007/s00018-019-03309-9
- https://doi.org//10.1038/362557a0
- https://doi.org//10.3389/fimmu.2018.02105
- https://doi.org//10.4049/jimmunol.0902294
- https://doi.org//10.1074/jbc.RA118.002800
- https://doi.org//10.1038/s41556-019-0348-8
- https://doi.org//10.1016/j.jneuroim.2007.09.033
- https://doi.org//10.4049/jimmunol.175.11.7650
- https://doi.org//10.1074/jbc.M807664200
- https://doi.org//10.4049/jimmunol.1101562
- https://doi.org//10.1074/jbc.M111.283580
- https://doi.org//10.1038/ncb825
- https://doi.org//10.3389/fncel.2020.00188
- https://doi.org//10.1038/s41598-017-11031-4
- https://doi.org//10.1111/j.1365-2443.2005.00827.x
- https://doi.org//10.1016/j.cell.2004.11.012
- https://doi.org//10.1128/MCB.25.22.9973-9984.2005
- https://doi.org//10.1074/jbc.M510934200
- https://doi.org//10.1016/j.febslet.2012.09.022
- https://doi.org//10.1247/csf.17025
- https://doi.org//10.1074/jbc.M513344200
- https://doi.org//10.1038/s41598-019-43658-w
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity